Cargando…
YAP and the Hippo pathway in cholangiocarcinoma
Cholangiocarcinoma (CCA) has an increasing incidence and remains a difficult to treat malignancy. In a search for more effective treatment options, progress has been made in identifying molecular drivers of oncogenic signaling including IDH mutations and FGFR2 fusions. In addition, multiple investig...
Autores principales: | Sugihara, Takaaki, Isomoto, Hajime, Gores, Gregory, Smoot, Rory |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536462/ https://www.ncbi.nlm.nih.gov/pubmed/30815737 http://dx.doi.org/10.1007/s00535-019-01563-z |
Ejemplares similares
-
YAP-associated chromosomal instability and cholangiocarcinoma in mice
por: Rizvi, Sumera, et al.
Publicado: (2017) -
The Multiple Interactions of RUNX with the Hippo–YAP Pathway
por: Chuang, Linda Shyue Huey, et al.
Publicado: (2021) -
Emerging Role of YAP and the Hippo Pathway in Prostate Cancer
por: Koinis, Filippos, et al.
Publicado: (2022) -
The Roles of YAP/TAZ and the Hippo Pathway in Healthy and Diseased Skin
por: Rognoni, Emanuel, et al.
Publicado: (2019) -
YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango
por: Matthaios, Dimitrios, et al.
Publicado: (2021)